March 26 (Reuters) - The U.S. Food and Drug Administration approved Soleno Therapeutics' SLNO.O drug to treat a rare genetic disorder on Wednesday, making it the first treatment available for patients who experience feelings of intense and persistent hunger.
(Reporting by Sneha S K and Bageshri Banerjee in Bengaluru; Editing by Krishna Chandra Eluri and Alan Barona)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。